Share on StockTwits

Covidien plc (NYSE:COV) has earned an average recommendation of “Hold” from the twenty analysts that are currently covering the stock, StockRatingsNetwork.com reports. Eleven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $87.54.

Several analysts have recently commented on the stock. Analysts at Citigroup Inc. reiterated a “buy” rating on shares of Covidien plc in a research note on Monday, July 28th. They now have a $101.00 price target on the stock, up previously from $81.00. Separately, analysts at Leerink Swann raised their price target on shares of Covidien plc from $93.00 to $95.00 in a research note on Monday, July 28th. They now have a “market perform” rating on the stock. Finally, analysts at RBC Capital raised their price target on shares of Covidien plc from $71.00 to $95.00 in a research note on Monday, July 28th.

Shares of Covidien plc (NYSE:COV) opened at 86.70 on Monday. Covidien plc has a 52-week low of $59.17 and a 52-week high of $92.68. The stock has a 50-day moving average of $87.62 and a 200-day moving average of $77.83. The company has a market cap of $39.167 billion and a P/E ratio of 26.27.

Covidien plc (NYSE:COV) last announced its earnings results on Friday, July 25th. The company reported $1.04 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.00 by $0.04. The company had revenue of $2.69 billion for the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter in the prior year, the company posted $0.91 earnings per share. The company’s quarterly revenue was up 4.3% on a year-over-year basis. On average, analysts predict that Covidien plc will post $4.02 earnings per share for the current fiscal year.

In other Covidien plc news, VP Coleman N. Lannum III purchased 3,338 shares of Covidien plc stock on the open market in a transaction dated Wednesday, August 27th. The stock was purchased at an average cost of $87.23 per share, for a total transaction of $291,173.74. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.